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Abstract: Machine learning is a branch of artiﬁ  cial intelligence that employs a variety of statistical, probabilistic and 
optimization techniques that allows computers to “learn” from past examples and to detect hard-to-discern patterns from 
large, noisy or complex data sets. This capability is particularly well-suited to medical applications, especially those that 
depend on complex proteomic and genomic measurements. As a result, machine learning is frequently used in cancer diag-
nosis and detection. More recently machine learning has been applied to cancer prognosis and prediction. This latter approach 
is particularly interesting as it is part of a growing trend towards personalized, predictive medicine. In assembling this review 
we conducted a broad survey of the different types of machine learning methods being used, the types of data being inte-
grated and the performance of these methods in cancer prediction and prognosis. A number of trends are noted, including 
a growing dependence on protein biomarkers and microarray data, a strong bias towards applications in prostate and breast 
cancer, and a heavy reliance on “older” technologies such artiﬁ  cial neural networks (ANNs) instead of more recently devel-
oped or more easily interpretable machine learning methods. A number of published studies also appear to lack an appropri-
ate level of validation or testing. Among the better designed and validated studies it is clear that machine learning methods 
can be used to substantially (15-25%) improve the accuracy of predicting cancer susceptibility, recurrence and mortality. 
At a more fundamental level, it is also evident that machine learning is also helping to improve our basic understanding of 
cancer development and progression.
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Introduction
Machine learning is not new to cancer research. Artiﬁ  cial neural networks (ANNs) and decision trees 
(DTs) have been used in cancer detection and diagnosis for nearly 20 years (Simes 1985; Maclin et al. 
1991; Ciccheti 1992). Today machine learning methods are being used in a wide range of applications 
ranging from detecting and classifying tumors via X-ray and CRT images (Petricoin and Liotta 2004; 
Bocchi et al. 2004) to the classiﬁ  cation of malignancies from proteomic and genomic (microarray) 
assays (Zhou et al. 2004; Dettling 2004; Wang et al. 2005). According to the latest PubMed statistics, 
more than 1500 papers have been published on the subject of machine learning and cancer. However, 
the vast majority of these papers are concerned with using machine learning methods to identify, clas-
sify, detect, or distinguish tumors and other malignancies. In other words machine learning has been 
used primarily as an aid to cancer diagnosis and detection (McCarthy et al. 2004). It has only been 
relatively recently that cancer researchers have attempted to apply machine learning towards cancer 
prediction and prognosis. As a consequence the body of literature in the ﬁ  eld of machine learning and 
cancer prediction/prognosis is relatively small (120 papers).
The fundamental goals of cancer prediction and prognosis are distinct from the goals of cancer 
detection and diagnosis. In cancer prediction/prognosis one is concerned with three predictive foci: 1) 
the prediction of cancer susceptibility (i.e. risk assessment); 2) the prediction of cancer recurrence and 
3) the prediction of cancer survivability. In the ﬁ  rst case, one is trying to predict the likelihood of devel-
oping a type of cancer prior to the occurrence of the disease. In the second case one is trying to predict 
the likelihood of redeveloping cancer after to the apparent resolution of the disease. In the third case 
one is trying to predict an outcome (life expectancy, survivability, progression, tumor-drug sensitivity) 
after the diagnosis of the disease. In the latter two situations the success of the prognostic prediction is 
obviously dependent, in part, on the success or quality of the diagnosis. However a disease prognosis 
can only come after a medical diagnosis and a prognostic prediction must take into account more than 
just a simple diagnosis (Hagerty et al. 2005).60
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Indeed, a cancer prognosis typically involves 
multiple physicians from different specialties using 
different subsets of biomarkers and multiple clini-
cal factors, including the age and general health of 
the patient, the location and type of cancer, as well 
as the grade and size of the tumor (Fielding et al. 
1992; Cochran 1997; Burke et al. 2005). Typically 
histological (cell-based), clinical (patient-based) 
and demographic (population-based) information 
must all be carefully integrated by the attending 
physician to come up with a reasonable prognosis. 
Even for the most skilled clinician, this is not easy 
to do. Similar challenges also exist for both physi-
cians and patients alike when it comes to the issues 
of cancer prevention and cancer susceptibility pre-
diction. Family history, age, diet, weight (obesity), 
high-risk habits (smoking, heavy drinking), and 
exposure to environmental carcinogens (UV radia-
tion, radon, asbestos, PCBs) all play a role in pre-
dicting an individual’s risk for developing cancer 
(Leenhouts 1999; Bach et al. 2003; Gascon et al. 
2004; Claus 2001; Domchek et al. 2003). Unfortu-
nately these conventional “macro-scale” clinical, 
environmental and behavioral parameters generally 
do not provide enough information to make robust 
predictions or prognoses. Ideally what is needed is 
some very speciﬁ  c molecular details about either 
the tumor or the patient’s own genetic make-up 
(Colozza et al. 2005).
With the rapid development of genomic (DNA 
sequencing, microarrays), proteomic (protein chips, 
tissue arrays, immuno-histology) and imaging 
(fMRI, PET, micro-CT) technologies, this kind of 
molecular-scale information about patients or 
tumors can now be readily acquired. Molecular 
biomarkers, such as somatic mutations in certain 
genes (p53, BRCA1, BRCA2), the appearance or 
expression of certain tumor proteins (MUC1, 
HER2, PSA) or the chemical environment of the 
tumor (anoxic, hypoxic) have been shown to serve 
as very powerful prognostic or predictive indicators 
(Piccart et al. 2001; Duffy 2001; Baldus et al. 
2004). More recently, combinations or patterns of 
multiple molecular biomarkers have been found to 
be even more predictive than single component 
tests or readouts (Savage and Gascoyne 2004; Pet-
ricoin and Liotta 2004; Duffy 2005; Vendrell et al. 
2005) If these molecular patterns are combined with 
macro-scale clinical data (tumor type, hereditary 
aspects, risk factors), the robustness and accuracy 
of cancer prognoses and predictions improves even 
more. However, as the number of parameters we 
measure grows, so too does the challenge of trying 
to make sense of all this information.
In the past, our dependency on macro-scale 
information (tumor, patient, population, and envi-
ronmental data) generally kept the numbers of 
variables small enough so that standard statistical 
methods or even a physician’s own intuition could 
be used to predict cancer risks and outcomes. 
However, with today’s high-throughput diagnostic 
and imaging technologies we now ﬁ  nd ourselves 
overwhelmed with dozens or even hundreds of 
molecular, cellular and clinical parameters. In these 
situations, human intuition and standard statistics 
don’t generally work. Instead we must increasingly 
rely on non-traditional, intensively computational 
approaches such as machine learning. The use of 
computers (and machine learning) in disease pre-
diction and prognosis is part of a growing trend 
towards personalized, predictive medicine (Weston 
and Hood 2004). This movement towards predic-
tive medicine is important, not only for patients 
(in terms of lifestyle and quality-of-life decisions) 
but also for physicians (in making treatment deci-
sions) as well as health economists and policy 
planners (in implementing large scale cancer pre-
vention or cancer treatment policies).
Given the growing importance of predictive 
medicine and the growing reliance on machine 
learning to make predictions, we believed it would 
be of interest to conduct a detailed review of pub-
lished studies employing machine learning meth-
ods in cancer prediction and prognosis. The intent 
is to identify key trends with respect to the types 
of machine learning methods being used, the types 
of training data being integrated, the kinds of end-
point predictions being made, the types of cancers 
being studied and the overall performance of these 
methods in predicting cancer susceptibility or 
patient outcomes. Interestingly, when referring to 
cancer prediction and prognosis we found that most 
studies were concerned with three “predictive” foci 
or clinical endpoints: 1) the prediction of cancer 
susceptibility (i.e. risk assessment); 2) the predic-
tion of cancer recurrence and 3) the prediction of 
cancer survivability. We also found that almost all 
predictions are made using just four types of input 
data: genomic data (SNPs, mutations, microarrays), 
proteomic data (speciﬁ  c protein biomarkers, 2D 
gel data, mass spectral analyses), clinical data 
(histology, tumor staging, tumor size, age, weight, 
risk behavior, etc.) or combinations of these three. 
In comparing and evaluating the existing studies 61
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a number of general trends were noted and a 
number of common problems detected. Some of 
the more obvious trends include a rapidly growing 
use of machine learning methods in cancer predic-
tion and prognosis (Figure 1), a growing reliance 
on protein markers and microarray data, a trend 
towards using mixed (proteomic + clinical) data, 
a strong bias towards applications in prostate and 
breast cancer, and an unexpected dependency on 
older technologies such as artiﬁ  cial neural net-
works (ANNs). Among the more commonly noted 
problems was an imbalance of predictive events 
with parameters (too few events, too many param-
eters), overtraining, and a lack of external valida-
tion or testing. Nevertheless, among the better 
designed and better validated studies it was clear 
that machine learning methods, relative to simple 
statistical methods, could substantially (15-25%) 
improve the accuracy of cancer susceptibility and 
cancer outcome prediction. In other words, 
machine learning has an important role to play in 
cancer prediction and prognosis.
Machine Learning Methods
Before beginning with a detailed analysis of what 
machine learning methods work best for which 
kinds of situations, it is important to have a good 
understanding of what machine learning is – and what 
it isn’t. Machine learning is a branch of artiﬁ  cial 
intelligence research that employs a variety of 
statistical, probabilistic and optimization tools to 
“learn” from past examples and to then use that prior 
training to classify new data, identify new patterns 
or predict novel trends (Mitchell 1997). Machine 
learning, like statistics, is used to analyze and inter-
pret data. Unlike statistics, though, machine learn-
ing methods can employ Boolean logic (AND, OR, 
NOT), absolute conditionality (IF, THEN, ELSE), 
conditional probabilities (the probability of X given 
Y) and unconventional optimization strategies to 
model data or classify patterns. These latter methods 
actually resemble the approaches humans typically 
use to learn and classify. Machine learning still 
draws heavily from statistics and probability, but it 
is fundamentally more powerful because it allows 
inferences or decisions to be made that could not 
otherwise be made using conventional statistical 
methodologies (Mitchell 1997; Duda et al. 2001). 
For instance, many statistical methods are based on 
multivariate regression or correlation analysis. 
While generally very powerful, these approaches 
assume that the variables are independent and that 
data can be modeled using linear combinations of 
these variables. When the relationships are nonlin-
ear and the variables are interdependent (or condi-
tionally dependent) conventional statistics usually 
ﬂ  ounders. It is in these situations where machine 
learning tends to shine. Many biological systems 
are fundamentally nonlinear and their parameters 
conditionally dependent. Many simple physical 
systems are linear and their parameters are essen-
tially independent.
Success in machine learning is not always guar-
anteed. As with any method, a good understanding 
of the problem and an appreciation of the limitations 
of the data is important. So too is an understanding 
of the assumptions and limitations of the algorithms 
being applied. If a machine learning experiment is 
properly designed, the learners correctly imple-
mented and the results robustly validated, then one 
usually has a good chance at success. Obviously if 
the data is of poor quality, the result will be of poor 
quality (garbage in = garbage out). Likewise if there 
are more variables than events to predict then it is 
also possible to create a series of redundant learners. 
This is a set of learning algorithms that seems to 
perform at the same (low) level regardless of the 
choice of input data. The problem of too many 
variables and too few examples is called the “curse 
of dimensionality” (Bellman 1961). This curse is 
not restricted to machine learning. It also affects 
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Figure 1. A histogram showing the steady increase in published 
papers using machine learning methods to predict cancer risk, recur-
rence and outcome. The data were collected using a variety of 
keyword searches through PubMed, CiteSeer, Google Scholar, 
Science Citation Index and other online resources. Each bar 
represents the cumulative total of papers published over a two year 
period. The earliest papers appeared in the early 1990’s.62
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many statistical methods as well. The only solution 
is to reduce the number of variables (features) or 
increase the number of training examples. As a 
general rule, the sample-per-feature ratio should 
always exceed 5:1 (Somorjai et al. 2003). Not only 
is the size of the training set important, so too is the 
variety of the training set. Training examples should 
be selected to span a representative portion of the 
data the learner expects to encounter. Training too 
many times on too few examples with too little 
variety leads to the phenomenon of over-training 
or simply training on noise (Rodvold et al. 2001). 
An over-trained learner, just like an overtired 
student, will generally perform poorly when it tries 
to process or classify novel data.
Sometimes conventional statistics proves to be 
more powerful or more accurate than machine 
learning. In these casesthe user's initial determina-
tions about the interdependence and nonlinearity 
of the data would have been wrong. This is not 
necessarily a weakness to machine learning, it is 
just a matter of choosing the right tool for the right 
job. Likewise, not all machine learning methods 
are created equal. Some are better for certain kinds 
of problems while others are better for other kinds 
of problems. For instance some machine learning 
algorithms scale nicely to the size of the biological 
domains, others do not. Likewise some methods 
may have assumptions or data requirements that 
render them inapplicable to the problem at hand. 
Knowing which method is best for a given problem 
is not inherently obvious. This is why it is critically 
important to try more than one machine learning 
method on any given training set. Another common 
misunderstanding about machine learning is that 
the patterns a machine learning tool ﬁ  nds or the 
trends it detects are non-obvious or not intrinsically 
detectable. On the contrary, many patterns or trends 
could be detected by a human expert – if they 
looked hard enough at the data. Machine learning 
simply saves on the time and effort needed to dis-
cover the pattern or to develop the classiﬁ  cation 
scheme. Recall that with any interesting discovery, 
it is frequently obvious to the casual observer – 
particularly after the discovery has been made.
There are three general types of machine learning 
algorithms: 1) supervised learning; 2) unsupervised 
learning and 3) reinforcement learning. They are 
essentially classiﬁ  ed on the basis of desired out-
come of the algorithm (Mitchell, 1997; Duda et al. 
2001). In supervised learning algorithms a 
“prescient provider” or teacher gives the learning 
algorithm a labeled set of training data or examples. 
These labeled examples are the training set that the 
program tries to learn about or to learn how to map 
the input data to the desired output. For instance a 
labeled training set might be a set of corrupted 
images of the number “8” (Figure 2). Since all the 
images are labeled as being the number “8” and the 
desired output is the uncorrupted “8”, the learner is 
able to train under the supervision of a teacher tell-
ing it what it is supposed to ﬁ  nd. This is the process 
by which most school children learn. In unsuper-
vised learning, a set of examples are given, but no 
labels are provided. Instead it is up to the learner to 
ﬁ  nd the pattern or discover the groups. This is 
somewhat analogous to the process by which most 
graduate students learn. Unsupervised learning 
algorithms include such methods as self-organizing 
feature maps (SOMs), hierarchical clustering and 
K-means clustering algorithms. These approaches 
create clusters from raw, unlabeled or unclassiﬁ  ed 
data. These clusters can be used later to develop 
classiﬁ  cation schemes or classiﬁ  ers.
The SOM approach (Kohonen 1982) is a spe-
cialized form of a neural network or ANN. It is 
based on using a grid of artiﬁ  cial neurons whose 
weights are adapted to match input vectors in a 
training set. In fact, the SOM was originally 
designed to model biological brain function (Koho-
nen 1982). A SOM begins with a set of artiﬁ  cial 
neurons, each havingits own physical location on 
the output map, which take part in a winner-take-
all process (a competitive network) where a node 
with its weight vector closest to the vector of inputs 
is declared the winner and its weights are adjusted 
making them closer to the input vector. Each node 
has a set of neighbors. When this node wins a 
competition, the neighbors’ weights are also 
changed, albeit to a lesser extent. The further the 
neighbor is from the winner, the smaller its weight 
change. This process is then repeated for each input 
vector for a large number of cycles. Different inputs 
produce different winners. The net result is a SOM 
which is capable of associating output nodes with 
speciﬁ  c groups or patterns in the input data set.
Interestingly, almost all machine learning algo-
rithms used in cancer prediction and prognosis 
employ supervised learning. Furthermore, most of 
these supervised learning algorithms belong to a 
speciﬁ  c category of classiﬁ  ers that classify on the 
basis of conditional probabilities or conditional 
decisions. The major types of conditional algo-
rithms include: 1) artificial neural networks 63
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(ANN – Rummelhart et al. 1986); 2) decision trees 
(DT – Quinlan, 1986); 3) genetic algorithms 
(GA – Holland 1975); 4) linear discriminant 
analysis (LDA) methods; 5) k-nearest neighbor 
algorithms prognosis with more than 820 of 1585 
surveyed papers using or referring to ANNs. First 
developed by McCulloch and Pitts (1943) and later 
popularized in the 1980’s by Rumelhart et al. 
(1986), ANNs are capable of handling a wide range 
of classiﬁ  cation or pattern recognition problems. 
Their strength lies in being able to perform a range 
of statistical (linear, logistic and nonlinear regres-
sion) and logical operations or inferences (AND, 
OR, XOR, NOT, IF-THEN) as part of the classiﬁ  -
cation process (Rodvold et al. 2001; Mitchell 
1997). ANNs were originally designed to model 
the way the brain works with multiple neurons 
being interconnected to each other through mul-
tiple axon junctions. Just as with biological 
learning, the strength of the neural connections is 
strengthened or weakened through repeated 
training or reinforcement on labeled training data. 
Mathematically, these neural connections can be 
represented as a wiring table or matrix (i.e. neuron 
1 is connected to neuron 2, 4 and 7; neuron 2 is 
connected to neuron 1, 5, 6 and 8, etc.). This weight 
matrix is called a layer, in analogy to the cortical 
layers in the brain. Neural networks typically use 
multiple layers (called hidden layers) to process their 
input and generate an output (Figure 2). To comply 
with the mathematical structure of each layer, input 
and output data is normally structured as a string, 
or vector, of numbers. One of the challenges in using 
ANNs is mapping how the real-world input/output 
(an image, a physical characteristic, a list of gene 
names, a prognosis) can be mapped to a numeric 
vector. In ANNs the adjustment of neural connection 
strengths is usually done via an optimization tech-
nique called back-propagation (short for backwards 
propagation of errors – Rumelhart et al. 1986). This 
is a derivative-based process that compares the 
output of one layer to the preceding layer’s table. In 
very simple terms the answers or labeled training 
data are used to progressively modify the numbers 
in the neural network’s weight matrices. A learning 
or information-transfer function (usually a sigmoi-
dal curve) that is easily differentiable is required for 
back propagation. Most ANNs are structured using 
a multi-layered feedforward architecture, meaning 
they have no feedback, or no connections that loop. 
The design and structure of an ANN must be cus-
tomized or optimized for each application. Simply 
choosing a generic ANN architecture or naively 
structuring a generic input/output schema can lead 
to very poor performance or extremely slow training. 
Another disadvantage of ANNs is the fact that they 
Training           Layer 1   Layer 2       Output 
Set 
nodes 
Figure 2. An example of how a machine learner is trained to recognize images using a training set (a corrupted image of the number “8”) 
which is labeled or identiﬁ  ed as the number “8”.64
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are a “black-box” technology. Trying to ﬁ  gure out 
why an ANN didn't work or how it performs its 
classiﬁ  cation is almost impossible to discern. In 
other words, the logic of a trained ANN is not easy 
to decipher.
In contrast to ANNs, the logic of decision trees 
(DTs) is very easy to discern. Formally a decision 
tree is a structured graph or ﬂ  ow chart of decisions 
(nodes) and their possible consequences (leaves or 
branches) used to create a plan to reach a goal 
(Quinlan, 1986; Mitchell 1997). Decision trees have 
been around for centuries (especially in taxonomy) 
and are a common component to many medical 
diagnostic protocols. An outline of a simple decision 
tree for breast cancer diagnosis is given in Figure 3. 
Normally decision trees are designed through con-
sultation with experts and reﬁ  ned through years of 
experience or modiﬁ  ed to comply with resource 
limitations or to limit risk. However decision tree 
learners also exist which can automatically construct 
decision trees given a labeled set of training data. 
When decision tree learners are used to classify data 
the leaves in the tree represent classiﬁ  cations and 
branches represent conjunctions of features that lead 
to those classiﬁ  cations. A decision tree can be learned 
by progressively splitting the labeled training data 
into subsets based on a numerical or logical test 
(Quinlan 1986). This process is repeated on each 
derived subset in a recursive manner until further 
splitting is either not possible, or a singular classiﬁ  -
cation is achieved. Decision trees have many advan-
tages: they are simple to understand and interpret, 
they require little data preparation, they can handle 
many types of data including numeric, nominal 
(named) and categorical data, they generate robust 
classiﬁ  ers, they are quick to “learn” and they can be 
validated using statistical tests. However DTs do not 
generally perform as well as ANNs in more complex 
classiﬁ  cation problems (Atlas et al. 1990).
A somewhat newer machine learning technique 
is called a support vector machine or SVM (Vapnik, 
1982; Cortes and Vapnik 1995; Duda et al. 2001). 
SVMs are well known in the world of machine 
learning but almost unknown in the ﬁ  eld of cancer 
prediction and prognosis (see Table 2). How an 
SVM works can best be understood if one is given 
a scatter plot of points, say of tumor mass versus 
number of axillary metastases (for breast cancer) 
among patients with excellent prognoses and poor 
prognoses (Figure 4). Two clusters are obviously 
evident. What the SVM machine learner would do 
is ﬁ  nd the equation for a line that would separate 
Lump detected
by self exam
Mammogram
suspicious 
Biopsy shows
malignancy
Self exam 
in 1 month
No biopsy
Non-malignant
cyst 
Lumpectomy +
Chemo 
No                                        Yes
No                                        Yes
No                                        Yes 
Figure 3. An example of a simple decision tree that might be used in breast cancer diagnosis and treatment. This is an example of a tree 
that might be formulated via expert assessment. Similar tree structures can be generated by decision tree learners.65
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the two clusters maximally. If one was plotting more 
variables (say volume, metastases and estrogen 
receptor content) the line of separation would 
become a plane. If more variables were included the 
separation would be deﬁ  ned by a hyperplane. The 
hyperplane is determined by a subset of the points 
of the two classes, called support vectors. Formally, 
the SVM algorithm creates a hyperplane that sepa-
rates the data into two classes with the maximum 
margin – meaning that the distance between the 
hyperplane and the closest examples (the margin) 
is maximized. SVMs can be used to perform non-
linear classiﬁ  cation using what is called a non-linear 
kernel. A non-linear kernel is a mathematical func-
tion that transforms the data from a linear feature 
space to a non-linear feature space. Applying dif-
ferent kernels to different data sets can dramatically 
improve the performance of an SVM classiﬁ  er. 
LikeANNs, SVMs can be used in a wide range of 
pattern recognition and classiﬁ  cation problems rang-
ing from hand writing analysis, speech and text 
recognition, protein function prediction and medical 
diagnosis (Duda et al. 2001). SVMs are particularly 
well suited to non-linear classiﬁ  cation problems, as 
are k-nearest neighbor approaches (see Table 1).
A Survey of Machine Learning 
Applications in Cancer Prediction
In preparing this review several electronic databases 
were accessed including PubMed (biomedical 
literature), the Science Citation Index (biomedical, 
engineering, computing and physico-chemical 
literature), CiteSeer (computing literature), Google 
and Google Scholar (web-accessible scientific 
literature). Query terms included “cancer and 
machine learning”, “cancer prediction and machine 
learning”, “cancer prognosis and machine learning”, 
“cancer risk assessment and machine learning” as 
well as multiple sub-queries with speciﬁ  c types of 
machine learning algorithms. The relevance of the 
individual papers was assessed by reading the titles 
and abstracts and identifying papers that used rec-
ognizable machine learning methods as well as 
molecular, clinical, histological, physiological or 
epidemiological data in carrying out a cancer prog-
nosis or prediction. Papers that focused on diagno-
ses or simple tumor classiﬁ  cations were excluded 
as were papers that had coincidental appearances of 
the words “machine” or “learning” in their abstracts. 
A PubMed search of “cancer and machine learning” 
yielded 1585 results, while searches of “cancer 
prediction and machine learning” and “cancer prog-
nosis and machine learning” yielded 174 and 240 
hits respectively. A detailed review of these abstracts 
led to the identiﬁ  cation of 103 relevant papers of 
which 71 could be accessed through various library 
holdings. Using CiteSeer, a search with the terms 
“cancer and machine learning” yielded 349 results, 
of which 12 (3.4%) were deemed relevant to cancer 
prognosis. Using Google Scholar, a search using 
“cancer prognosis and ‘machine learning’” yielded 
996 results, of which 49 (4.9%) were judged relevant 
to cancer prognosis. Many of these papers were 
previously identiﬁ  ed in the PubMed searches as 
were the vast majority of the hits in the Science 
Citation Index searches. From the initial group of 
papers identiﬁ  ed from these electronic searches, 
their reference lists were further consulted to iden-
tify additional papers of interest or relevance. In the 
end more than 120 relevant papers, going as far back 
as 1989, were identiﬁ  ed. Of these, 79 papers could 
be accessed from existing library holdings and were 
selected for more detailed analysis (Table 2). While 
it is impossible to be certain that we achieved com-
plete coverage of all literature on machine learning 
and cancer prediction/prognosis, we believe that a 
signiﬁ  cant portion of the relevant literature has been 
assessed for this review.
From our analysis of the literature several trends 
were noted. As has been remarked previously, the use 
of machine learning in cancer prediction and progno-
sis is growing rapidly, with the number of papers 
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Figure 4. A simpliﬁ  ed illustration of how an SVM might work in 
distinguishing between basketball players and weightlifters using 
height/weight support vectors. In this simple case the SVM has 
identiﬁ  ed a hyperplane (actually a line) which maximizes the separa-
tion between the two clusters.66
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Table 1. Summary of beneﬁ  ts, assumptions and limitations of different machine learning algorithms
Machine Learning 
Algorithm Beneﬁ  ts Assumptions and/or Limitations
Decision Tree 
(Quinlan 1986)
•   easy to understand and efﬁ  cient
training algorithm
•   order of training instances has 
no effect on training
•   pruning can deal with the 
problem of overﬁ  tting
•   classes must be mutually exclusive
•   ﬁ  nal decision tree dependent upon order 
of attribute selection
•   errors in training set can result in overly 
complex decision trees
•   missing values for an attribute make it 
unclear about which branch to take when 
that attribute is tested
Naïve Bayes 
(Langley et al 1992)
•   foundation based on statistical 
modelling
•   easy to understand and efﬁ  cient 
training algorithm
•   order of training instances has
no effect on training
•   useful across multiple domains
•   assumes attributes are statistically 
independent*
•   assumes normal distribution on numeric 
attributes
•   classes must be mutually exclusive
•   redundant attributes mislead classiﬁ  cation
•   attribute and class frequencies affect 
accuracy
k-Nearest Neighbour 
(Patrick & Fischer 1970; 
Aha 1992)
•   fast classiﬁ  cation of instances
•   useful for non-linear
classiﬁ  cation problems
•   robust with respect to irrelevant
or novel attributes
•   tolerant of noisy instances or
instances with missing attribute
values
•   can be used for both regression
and classiﬁ  cation
•   slower to update concept description
•   assumes that instances with similar 
attributes will have similar classiﬁ  cations
•   assumes that attributes will be equally 
relevant
•   too computationally complex as number of 
attributes increases
Neural Network 
(Rummelhart et al 1986)
•   can be used for classiﬁ  cation
or regression
•   able to represent Boolean
functions (AND, OR, NOT)
•   tolerant of noisy inputs
•   instances can be classiﬁ  ed by
more than one output
•   difﬁ  cult to understand structure of 
algorithm
•   too many attributes can result in 
overﬁ  tting
•   optimal network structure can only be 
determined by experimentation
Support Vector Machine 
(Vapnik 1982; Russell and 
Norvig, p 749-52)
•   models nonlinear class
boundaries
•   overﬁ  tting is unlikely to occur
•   computational complexity
reduced to quadratic optimization 
problem
•   easy to control complexity of
decision rule and frequency 
of error
•   training is slow compared to Bayes and 
Decision Trees
•   difﬁ  cult to determine optimal parameters 
when training data is not linearly 
separable
•   difﬁ  cult to understand structure of 
algorithm
Genetic Algorithm 
(Holland 1975)
•   simple algorithm, easy to
implement
•   can be used in feature
classiﬁ  cation and feature
selection
•   primarily used in optimization
•   always ﬁ  nds a “good” solution 
(not always the best solution)
•   computation ordevelopment of scoring 
function is non trivial
•   not the most efﬁ  cient method to ﬁ  nd some 
optima, tends to ﬁ  nd local optima 
rather than global
•   complications involved in the 
representation of training/output data
increasing by 25% per year (Figure 1). While it is clear 
that machine learning applications in cancer predic-
tion and prognosis are growing, so too is the use of 
standard statistically-based predictive methods.
In particular, we looked at the frequency with 
which “cancer prediction prognosis methods” and 
“cancer risk assessment prediction methods” 
occurred in PubMed. These queries yielded 
1061 and 157 hits respectively, giving a non-
overlapping set of 1174 papers. Removing the 53 
papers with machine learning components in this 
set, we were left with 1121 papers. While a detailed 67
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review of each abstract was not possible, a random 
sampling indicated that ~80% of these papers were 
relevant (890 papers) in that they used statistical 
approaches to predict or prognosticate cancer 
outcomes. Therefore these data suggest that 
machine learning methods account for 103/890 
(11%) of all PubMed papers describing cancer 
prediction or prognosis methodology. Overall, the 
same yearly growth trends (i.e. near exponential) 
in prediction and prognosis were observed for the 
statistical methods as for the machine learning 
methods.
When looking at the types of predictions or 
prognoses being made, the vast majority (86%) are 
associated with predicting cancer mortality (44%) 
and cancer recurrence (42%). However, a growing 
number of more recent studies are now aimed at 
predicting the occurrence of cancer or the risk fac-
tors associated with developing cancer. As a gen-
eral rule, regardless of the machine learning 
method used, the type of prediction being made or 
the type of cancer being evaluated, machine learn-
ing methods appear to improve the accuracy of 
predictions by and average of 15-25% over alterna-
tive or conventional approaches (Table 2).
In assessing how these predictions were made 
it appears that the majority (53%) studies relied 
on clinical (cancer staging, cellular histology, 
nuclear markers) or demographic data (age, 
weight, smoking) – either alone or in combination 
with other molecular biomarkers. While histo-
logical data is generally more accessible, the 
ambiguity or pathologist-speciﬁ  c peculiarities of 
many histopathological assessments almost 
always makes it difﬁ  cult to generalize or transfer 
a machine learning tool trained on this kind of data 
to other clinical settings. Given the limitations of 
using histological assessments in machine learn-
ing, there is an encouraging trend among more 
recent studies to use more robustly measurable 
features such as speciﬁ  c protein markers, gene 
mutations and gene expression values as input 
data. Approximately 47% of studies used this 
molecular (i.e. proteomic or genomic) data either 
alone (25%) or in combination (22%) with clinical 
data. Given the precision of most molecular assays 
(with the possible exception of microarray data), 
we believe the results from these studies should 
be more easily or robustly transferable to other 
clinical settings.
As seen in Figure 5, there is strong bias among 
scientists to use machine learning towards predicting 
outcomes or risks associated with breast (24%) 
and prostate (20%) cancer. This, no doubt, reﬂ  ects 
the higher frequency of these cancers among 
patients in Europe and North America. Neverthe-
less, machine learning methods appear to have 
been successfully used in predicting outcomes or 
risks in nearly a dozen different kinds of cancer. 
This suggests that machine learning methods can 
be quite generally applied to cancer prediction and 
prognosis. Figure 5 also illustrates the distribution 
of the types of machine learning methods applied 
to different kinds of cancer predictions. Almost 
70% of all reported studies use neural networks 
as their primary (and sometimes only) predictor. 
Support vector machines are a distant second with 
9%, while clustering and decision trees each 
account for about 6%. Genetic algorithms and 
other methods (naïve Bayes, fuzzy logic) are rarely 
used (Table 2). This is both surprising and a bit 
disappointing. ANNs are relatively old machine 
learning technologies which yield so-called 
“black-box” results. That is, their performance and 
classiﬁ  cation processes are not easily explained or 
rationalized. The existence of other methods 
(SVMs, DTs, NBs) which inherently provide easily 
accessible explanations appears not to be widely 
known among cancer informaticians. Overall, 
many of the papers reviewed for this survey were 
of generally high quality. Some of the better papers 
are discussed in more detail under the “Case Stud-
ies” section of this review. However, a disturbing 
number of studies lacked sufﬁ  cient internal or 
external validation, were trained on far too few 
examples, tested on only a single machine learner 
or had no well-deﬁ  ned standard with which to 
compare the performance of the reported algo-
rithm. These problems are discussed in more 
detail under the section entitled “Limitations and 
Lessons”.
Case Study 1 – Cancer Risk 
or Susceptibility Prediction
Of the 79 papers surveyed in this review, relatively 
few papers (just 3) employed machine learning to 
predict cancer risk susceptibility. One of the more 
interesting papers (Listgarten et al. 2004), used 
single nucleotide polymorphism (SNP) proﬁ  les 
of steroid metabolizing enzymes (CYP450s) 
to develop a method to retrospectively predict 
the occurrence of “spontaneous” breast cancer. 
Spontaneous or non-familial breast cancer accounts 68
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for about 90% of all breast cancers (Dumitrescu 
and Cotarla 2005). The hypothesis in this study 
was that certain combinations of steroid-metabo-
lism gene SNPs would lead to the increased accu-
mulation of environmental toxins or hormones in 
breast tissue leading to a higher risk for breast 
cancer. The authors collected SNP data (98 SNPs 
from 45 different cancer-associated genes) for 
63 patients with breast cancer and 74 patients 
without breast cancer (control). Key to the success 
of this study was the fact that the authors employed 
several methods to reduce the sample-per-feature 
ratio and investigated multiple machine learning 
methods to ﬁ  nd an optimal classiﬁ  er. Speciﬁ  cally, 
from a starting set of 98 SNPs the authors quickly 
reduced this set to just 2-3 SNPs that seemed 
maximally informative. This reduced the sample-
per-feature ratio to a respectable 45:1 (for 3 SNPs) 
and 68:1 (for 2 SNPs) instead of close to 3:2 (had 
all 98 SNPs been used). This allowed the study to 
avoid falling victim to the “curse of dimensional-
ity” (Bellman 1961; Somorjai etal. 2003). Once 
the sample size was reduced, several machine 
learning techniques were employed including a 
naïve Bayes model, several decision tree models 
and a sophisticated support vector machine (SVM). 
The SVM and naïve Bayes classiﬁ  ers attained the 
highest accuracy using only a set of 3 SNPs and 
the decision tree classiﬁ  er attained the highest 
accuracy using a set of 2 SNPs. The SVM classiﬁ  er 
performed the best with an accuracy of 69%, while 
the naïve Bayes and decision tree classifiers 
achieved accuracies of 67% and 68%, respectively. 
These results are approximately 23-25% better than 
chance. Another notable feature to this study was 
the extensive level of cross validation and conﬁ  r-
mation performed. The predictive power of each 
model was validated in at least three ways. Firstly, 
the training of the models were assessed and 
monitored with 20-fold cross-validation. A boot-
strap resampling method was employed by per-
forming the cross-validation 5 times and averaging 
the results so as to minimize the stochastic element 
involved with partitioning of the samples. Sec-
ondly, to minimize the bias in feature selection (i.e. 
selecting the most informative subset of SNPs), 
the selection process was performed within each 
fold for a total of 100 times (5 times for each of 
the 20 folds). Finally, the results were compared 
against a random permutation test which at best, 
had a predictive accuracy of 50%. While the 
authors attempted to minimize the stochastic ele-
ment involved with partitioning of the samples, a 
better method may have been to use leave-one-out 
cross-validation which would have removed this 
stochastic element completely. That being said, the 
multiple cross-validations resulted in a standard 
deviation that was not more than 4% for any of the 
reported accuracies and since all the methods per-
formed close to 25% better than chance, this stan-
dard deviation is deemed negligible. While no 
external validation set was reported in this study, 
we have recently learned that the results described 
in this paper have been duplicated with a simi-
lar follow-on study of another 200 individuals 
(S. Damaraju, personal communication). Overall, 
this study nicely illustrates how the proper design, 
careful implementation, appropriate data selec-
tion and thorough validation of multiple machine 
learners can produce a robust and accurate cancer-
risk prediction tool. It also highlights how machine 
learning can reveal important insights into the 
biology and polygenic risk factors associated with 
spontaneous or non-familial breast cancer.
Case Study 2: Prediction of Cancer 
Survivability
Nearly half of all machine learning studies on 
cancer prediction were focused on predicting 
0%
5%
10%
15%
20%
25%
30%
b
l
a
d
d
e
r
b
r
e
a
s
t
c
o
l
o
r
e
c
t
a
l
l
i
v
e
r
l
u
n
g
l
y
m
p
h
o
m
a
p
r
o
s
t
a
t
e
s
k
i
n
t
h
r
o
a
t
o
t
h
e
r
Type of Cancer
P
e
r
c
e
n
t
a
g
e
 
o
f
 
P
a
p
e
r
s
Naïve Bayes
Genetic Algorithm
Fuzzy Logic
Clustering
Decision Tree
SVM
ANN
Figure 5. A histogram showing the frequency with which different 
types of machine learning methods are used to predict different types 
of cancer. Breast and prostate cancer dominate, however a good 
range of cancers from different organs or tissues also appear to be 
compatible with machine learning prognoses. The “other” cancers 
include brain, cervical, esophageal, leukemia, head, neck, ocular, 
osteosarcoma, pleural mesothelioma, thoracic, thyroid, and trophob-
lastic (uterine) malignancies. Figure 1.69
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patient survivability (either 1 year or 5 year sur-
vival rates). One paper of particular interest (Futs-
chik et al. 2003) used a hybrid machine learning 
approach to predict outcomes for patients with 
diffuse large B-cell lymphoma (DLBCL). Spe-
ciﬁ  cally, both clinical and genomic (microarray) 
data were combined to create a single classiﬁ  er to 
predict survival of DLBCL patients. This approach 
differs somewhat from the study of Listgarten et al. 
(2004) which only employed genomic (SNP) data 
in its classiﬁ  er schema. Futschik et al. hypothe-
sized, correctly, that clinical information could 
enrich microarray data such that a combined pre-
dictor would perform better than a classiﬁ  er based 
on either microarray data alone or clinical data 
alone. In assembling the test and training samples, 
the authors collected microarray expression data 
and clinical information for 56 DLBCL patients. 
The clinical information was obtained from the 
International Prediction Index (IPI) which consists 
of a set of risk factors, that when properly assessed, 
allows patients to be separated into groups rang-
ing from low-risk to high-risk. The data from 
the patient’s IPI classiﬁ  cations was then used to 
create a simple Bayesian classiﬁ  er. This classiﬁ  er 
achieved an accuracy of 73.2% in predicting the 
mortality of DLBCL patients. Separately from the 
Bayesian classifier, several different types of 
“evolving fuzzy neural network” (EFuNN) classi-
ﬁ  ers were also developed to handle the genomic 
data. The best EFuNN classiﬁ  er used a subset of 
17 genes from the microarray data. This optimal 
EFuNN had an accuracy of 78.5%. The EFuNN 
classiﬁ  er and the Bayesian classiﬁ  er were then 
combined into a hierarchical modular system to 
generate a consensus prediction. This hybrid clas-
sifier attained an accuracy of 87.5%, a clear 
improvement over the performance of either clas-
siﬁ  er alone. This was also 10% better than the 
best performing machine learning classiﬁ  er (77.6% 
by SVMs).
The EFuNN classiﬁ  er was validated using a 
leave-one-out cross-validation strategy. This was 
likely due to the small sample size. As with Case 
Study #1, no external validation set was available 
to test the generality of the model. With only 
56 patients (samples) being classiﬁ  ed via 17 gene 
features, the sample per feature ratio (SFR) is just 
over 3. As a rule, an SFR of less than 5 does not 
necessarily guarantee a robust classiﬁ  er (Somorjai 
et al. 2003). However, it is quite evident that 
the authors were aware of this issue and went to 
considerable lengths to justify their approach by 
explaining, in detail, the inner workings of their 
classiﬁ  er. This included a description of how the 
Bayesian classiﬁ  er was built, how the EFuNN 
works, and how the two classiﬁ  ers work together 
to give a single prediction. In addition, the authors 
also investigated, and subsequently conﬁ  rmed, the 
independence of the microarray data from the 
clinical data. This attention to detail is particularly 
exemplary for a machine learning investigation of 
this kind. This study nicely demonstrates how the 
power of using both clinical and genomic data in 
cancer prognosis can substantially enhance predic-
tion accuracy.
Case Study 3: Prediction of Cancer 
Recurrence
A total of 43% of the studies analyzed for this 
review applied machine learning towards the 
prediction of cancer relapse or recurrence. One 
particularly good example is the study of De Lau-
rentiis et al. (1999), which actually addresses some 
of the drawbacks noted in the previous studies. 
These authors aimed to predict the probability of 
relapse over a 5 years period for breast cancer 
patients. A combination of 7 prognostic variables 
was used including clinical data such as patient 
age, tumor size, and number of axillary metastases. 
Protein biomarker information such as estrogen 
and progesterone receptor levels was also included. 
The aim of the study was to develop an automatic, 
quantitative prognostic method that was more reli-
able than the classical tumor-node-metastasis 
(TNM) staging system. TNM is a physician-based 
expert system that relies heavily on the subjective 
opinion of a pathologist or expert clinician. The 
authors employed an ANN-based model that used 
data from 2441 breast cancer patients (times 7 data 
points each) yielding a data set with more than 
17,000 data points. This allowed the authors to 
maintain a sample-to-feature ratio of well over the 
suggested minimum of 5 (Somorjai et al. 2003). 
The entire data set was partitioned into three equal 
groups: training (1/3), monitoring (1/3), and test 
sets (1/3) for optimization and validation. In addi-
tion, the authors also obtained a separate set of 310 
breast cancer patient samples from a different 
institution, for external validation. This allowed 
the authors to assess the generalizability of their 
model outside their institution—a process not done 
by the two previously discussed studies.70
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This study is particularly notable not only for 
the quantity of data and the thoroughness of valida-
tion, but also for the level of quality assurance 
applied to the data handling and processing. For 
instance, the data was separately entered and stored 
in a relational database and all of it was indepen-
dently veriﬁ  ed by the referring physicians to main-
tain quality. With 2441 patients and 17,000 data 
points in the data set, the sample size was sufﬁ  -
ciently large that a normal population distribution 
of breast cancer patients could be assumed within 
the data set, even after partitioning. Regardless, 
the authors explicitly veriﬁ  ed this assumption by 
looking at the distribution of the data for the 
patients within each set (training, monitoring, test, 
and external) and showed that the distributions 
were relatively similar. This quality assurance and 
attention to detail allowed the authors to develop 
a very accurate and robust classiﬁ  er.
Since the aim of the study was to develop a model 
that predicted relapse of breast cancer better than 
the classical TNM staging system, it was important 
for the ANN model to be compared to TNM staging 
predictions. This was done by comparing the per-
formance using a receiver operator characteristic 
(ROC) curve. The ANN model (0.726) was found 
to outperform the TNM system (0.677) as measured 
by the area under the ROC curve. Thi s study is an 
excellent example of a well-designed and well-
tested application of machine learning. A sufﬁ  ciently 
large data set was obtained and data for each sample 
was independently veriﬁ  ed for quality assurance 
and accuracy. Furthermore, blinded sets for valida-
tion were available from both the original data set 
and from an external source to assess the generality 
of the machine learning model. Finally, the accuracy 
of the model was explicitly compared to that of a 
classical prognostic scheme, TNM staging. Perhaps 
the one drawback to this study was the fact that the 
authors only tested a single kind of machine learning 
(ANN) algorithm. Given the type and quantity of 
data used, it is quite possible that their ANN model 
may have been outperformed by another machine 
learning technique.
Lessons, Limitations 
and Recommendations
The 3 case studies outlined in the preceding pages 
are just a few examples of how well-designed 
machine learning experiments should be conducted 
and how the methods and results should be 
described, validated and assessed – especially in 
cancer prediction and prognosis. There are obvi-
ously many other examples of equally good stud-
ies with equally impressive results (see Table 2). 
However, it is also important to note that not all 
machine learning studies are conducted with the 
same rigor or attention to detail as with these case 
studies. Being able to identify potential problems 
in either the experimental design, validation or 
learner implementation is critical not only for those 
wishing to use machine learning, but also for those 
needing to evaluate different studies or to assess 
different machine learning options.
One of the most common problems seen among 
the studies surveyed in this review was the lack of 
attention paid to data size and learner validation. 
In other words, there are a number of studies with 
sloppy experimental design. A minimum require-
ment for any machine learning exercise is having 
a sufﬁ  ciently large data set that can be partitioned 
into disjoint training and test sets or subjected to 
some reasonable form of n-fold cross-validation 
for smaller data sets. Typically 5-fold (iteratively 
taking 20% of the training data out to serve as test-
ing data) or 10-fold cross-validation (iteratively 
taking 10% of the training data out to serve as test-
ing data) is sufﬁ  cient to validate most any learning 
algorithm. This kind of rigorous internal validation 
is critical to creating a robust learner that can con-
sistently handle novel data. Beyond the standard 
practice of internal validation, it is particularly 
beneﬁ  cial to perform a validation test using an 
external data source. External validation is an 
important “sanity” check and it also helps to catch 
or minimize any bias that may be imposed by site 
or person-speciﬁ  c clinical measurement practices. 
Of course, this external validation set must also be 
of sufﬁ  ciently large size to ensure reproducibility.
As has been frequently noted before, the size of 
a given training set has several implications per-
taining to robustness, reproducibility and accuracy. 
The ﬁ  rst implication is that for a smaller sample 
size, almost any model is prone to overtraining. 
Overtraining can lead to reported accuracies that 
may be misleading or erroneous. For instance, one 
early study reported only a single misclassiﬁ  cation 
during the training and testing of an ANN for pre-
dicting the survival of hepatectomized patients 
using 9 separate features (Hamamoto et al. 1995). 
However, the entire data set (training and testing) 
consisted of just 58 patients. This particular study 
then used an external data set to validate the 71
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model where the authors prospectively predicted 
the survival outcome with 100% accuracy.
However, the external test set only consisted of 
11 patients. The fact that 100% accuracy is attained 
for a prospective prediction is impressive, but 
given the size of the validation set and the small 
sample-per-feature ratio, some doubt may be cast 
on the robustness of the predictor. Certainly a larger 
validation set would be desirable to reinforce the 
claim of 100% accuracy. In another example, only 
28 cases were used to build an ANN for predicting 
throat cancer recurrence that made use of the 
expression levels of 60 genes from microarray data 
(Kan et al. 2004). The accuracy of the model was 
claimed to be 86%, but this is particularly suspect 
given the very small sample size. Indeed it is quite 
likely that this ANN was over-trained.
The size of a given data set also signiﬁ  cantly 
affects the sample-per-feature ratio. As a rule, the 
sample-per-feature ratio should be at least 5-10 
(Somorjai et al. 2003). Small sample-per-feature 
ratios are a particularly big problem for microarray 
studies, which often have thousands of genes (ie 
features), but only hundreds of samples. The study 
by Ohira et al. (2005) provides one such example 
of the problems one may encounter trying to pro-
cess too much microarray data. These authors 
created a probabilistic output statistical classiﬁ  er 
to predict prognosis of neuroblastoma patients 
using microarray data from 136 tumor samples. 
Each microarray had 5340 genes, leading to a 
sample-per-feature ratio of ~0.025. A sample-per-
feature ratio this small is highly susceptible to the 
problems of overtraining. Furthermore, with a 
sample-per-feature ratio of this size it is also pos-
sible to develop highly redundant classiﬁ  cation 
models which perform equally well despite being 
trained on different subsets of genes. The problem 
with redundant models is that the robustness of any 
one model cannot be guaranteed as more test cases 
become available.
Data size is not the only limitation for effective 
machine learning. Data set quality and careful 
feature selection are also equally important (recall: 
“garbage in=garbage out”). For large data sets data 
entry and data veriﬁ  cation are of paramount impor-
tance. Often careless data entry can lead to simple 
off-by-one errors in which all the values for a 
particular variable are shifted up or down by one 
row in a table. This is why independent veriﬁ  cation 
by a second data-entry curator or data checker is 
always beneficial. Further verification or spot 
checking of data integrity by a knowledgeable 
expert, not just a data entry clerk, is also a valuable 
exercise. Unfortunately, the methods employed to 
ensure data quality and integrity are rarely dis-
cussed in most machine learning papers.
Just as data quality is important so too is feature 
quality. Certainly the subset of features chosen to 
train a model could mean the difference between 
a robust, accurate model and one that is ﬂ  awed and 
inaccurate. Ideally features should be chosen that 
are reproducible and precisely measurable from 
one lab (or clinic) to the next. One study (Delen 
et al. 2005) used “primary site code” and “site 
speciﬁ  c surgery code” as features to predict breast 
cancer survivability. While these clinical features 
may be helpful in determining the outcome for 
breast cancer patients at this particular hospital, 
for this moment in time, they may become irrele-
vant overtime. Even worse, if new site codes or 
site speciﬁ  c surgery codes are created, the model 
will have to be re-trained to account for the new 
codes. Similar feature selection problems often 
occur with histological assessments. As good as 
many pathologists are there is always some incon-
sistency (up to 30% in many cases) between dif-
ferent histopathological assessments from different 
sites or different pathologists. As a rule, the best 
features are those that are highly reproducible, 
universal or absolute (age, gender, weight, certain 
biomarker measurements, etc). Even with these 
seemingly robust features it is important to remem-
ber that clinical data sets are not static entities. 
With time the importance or relevance of these 
clinical measures may evolve over time with some 
features being added, modiﬁ  ed or deleted. There-
fore a classiﬁ  er must also be able to adapt to dif-
ferent feature sets over time too.
Another important lesson that was learned from 
assessing many of these machine learning papers 
was the value of using multiple predictor models 
based on different machine learning techniques. 
While ANNs are often considered to be very 
sophisticated and advanced machine learning 
methods, ANNs are not always the best tools for 
the job. Sometimes simpler machine learning 
methods, like the naïve Bayes and decision tree 
methods can substantially outperform ANNs 
(Delen et al. 2005). Assessing the performance 
of a machine learning predictor against other 
predictors is critical to choosing the optimal tool. 
It is also critical to deciding if the method is any 
better than previously existing schemes. Ideally, 72
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Table 2: Survey of machine learning methods used in cancer prediction showing the types of cancer, clinical 
endpoints, choice of algorithm, performance and type of training data.
Cancer 
Type
Clinical 
Endpoint
Machine 
Learning 
Algorithm Benchmark
Improvement 
(%)
Training
Data Reference
bladder recurrence fuzzy logic statistics 16 mixed Catto et al, 2003
bladder recurrence ANN N/A N/A clinical Fujikawa et al, 2003
bladder survivability ANN N/A N/A clinical Ji et al, 2003
bladder recurrence ANN N/A N/A clinical Spyridonos et al, 2002
brain survivability ANN statistics N/A genomic Wei et al, 2004
breast recurrence clustering statistics N/A mixed Dai et al, 2005
breast survivability decision 
tree
statistics 4 clinical Delen et al, 2005
breast susceptibility SVM random 19 genomic Listgarten et al, 2004
breast recurrence ANN N/A N/A clinical Mattfeldt et al, 2004
breast recurrence ANN N/A N/A mixed Ripley et al, 2004
breast recurrence ANN statistics 1 clinical Jerez-Aragones et al, 
2003
breast survivability ANN statistics N/A clinical Lisboa et al, 2003
breast treatment 
response
ANN N/A N/A proteomic Mian et al, 2003
breast survivability clustering statistics 0 clinical Seker et al, 2003
breast survivability fuzzy logic statistics N/A proteomic Seker et al, 2002
breast survivability SVM N/A N/A clinical Lee et al, 2000
breast recurrence ANN expert 5 mixed De Laurentiis et al, 
1999
breast survivability ANN statistics 1 clinical Lundin et al, 1999
breast recurrence ANN statistics 23 mixed Marchevsky et al, 1999
breast recurrence ANN N/A N/A clinical Naguib et al, 1999
breast survivability ANN N/A N/A clinical Street, 1998
breast survivability ANN expert 5 clinical Burke et al, 1997
breast recurrence ANN statistics N/A mixed Mariani et al, 1997
breast recurrence ANN expert 10 clinical Naguib et al, 1997
cervical survivability ANN N/A N/A mixed Ochi et al, 2002
colorectal recurrence ANN statistics 12 clinical Grumett et al, 2003
colorectal survivability ANN statistics 9 clinical Snow et al, 2001
colorectal survivability clustering N/A N/A clinical Hamilton et al, 1999
colorectal recurrence ANN statistics 9 mixed Singson et al, 1999
colorectal survivability ANN expert 11 clinical Bottaci et al, 1997
esophageal treatment 
response
SVM N/A N/A proteomic Hayashida et al, 2005
esophageal survivability ANN statistics 3 clinical Sato et al, 2005
leukemia recurrence decision 
tree
N/A N/A proteomic Masic et al, 1998
liver recurrence ANN statistics 25 genomic Rodriguez-Luna et al, 
2005
liver recurrence SVM N/A N/A genomic Iizuka et al, 2003
liver susceptibility ANN statistics -2 clinical Kim et al, 2003
liver survivability ANN N/A N/A clinical Hamamoto et al, 1995
lung survivability ANN N/A N/A clinical Santos-Garcia et al, 
2004
lung survivability ANN statistics 9 mixed Hanai et al, 2003
lung survivability ANN N/A N/A mixed Hsia et al, 2003
lung survivability ANN statistics N/A mixed Marchevsky et al, 1998
lung survivability ANN N/A N/A clinical Jefferson et al, 1997
lymphoma survivability ANN statistics 22 genomic Ando et al, 2003
lymphoma survivability ANN expert 10 mixed Futschik et al, 2003
lymphoma survivability ANN N/A N/A genomic O’Neill and Song, 2003
lymphoma survivability ANN expert N/A genomic Ando et al, 2002
lymphoma survivability clustering N/A N/A genomic Shipp et al, 2002
head/neck survivability ANN statistics 11 clinical Bryce et al, 199873
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Table 2: Continued.
Cancer Type
Clinical 
Endpoint
Machine 
Learning 
Algorithm Benchmark
Improvement 
(%)
Training 
Data Reference
neck treatment 
response
ANN N/A N/A clinical Drago et al, 2002
ocular survivability SVM N/A N/A genomic Ehlers and Harbour, 
2005
osteo-
sarcoma
treatment 
response
SVM N/A N/A genomic Man et al, 2005
pleural 
mesothelioma
survivability clustering N/A N/A genomic Pass et al, 2004
prostate treatment 
response
ANN N/A N/A mixed Michael et al, 2005
prostate recurrence ANN statistics 0 clinical Porter et al, 2005
prostate treatment 
response
ANN N/A N/A clinical Gulliford et al, 2004
prostate recurrence ANN statistics 16 mixed Poulakis et al, 2004a
prostate recurrence ANN statistics 11 mixed Poulakis et al, 2004b
prostate recurrence SVM statistics 6 clinical Teverovskiy et al, 2004
prostate recurrence ANN statistics 0 clinical Kattan, 2003
prostate recurrence genetic 
algorithm
N/A N/A mixed Tewari et al, 2001
prostate recurrence ANN statistics 0 clinical Ziada et al, 2001
prostate susceptibility decision 
tree
N/A N/A clinical Crawford et al, 2000
prostate recurrence ANN statistics 13 clinical Han et al, 2000
prostate treatment 
response
ANN N/A N/A proteomic Murphy et al, 2000
prostate recurrence naïve 
Bayes
statistics 1 clinical Zupan et al, 2000
prostate recurrence ANN N/A N/A clinical Mattfeldt et al, 1999
prostate recurrence ANN statistics 17 clinical Potter et al, 1999
prostate recurrence ANN N/A N/A mixed Naguib et al, 1998
skin survivability ANN expert 14 clinical Kaiserman et al, 2005
skin recurrence ANN expert 27 proteomic Mian et al, 2005
skin survivability ANN expert 0 clinical Taktak et al, 2004
skin survivability genetic 
algorithm
N/A N/A clinical Sierra and Larranga, 
1998
stomach recurrence ANN expert 28 clinical Bollschweiler et al, 
2004
throat recurrence fuzzy logic N/A N/A clinical Nagata et al, 2005
throat recurrence ANN statistics 0 genomic Kan et al, 2004
throat survivability decision 
tree
statistics N/A proteomic Seiwerth et al, 2000
thoracic treatment 
response
ANN N/A N/A clinical Su et al, 2005
thyroid survivability decision 
tree
statistics N/A clinical Kukar et al, 1997
tropho- survivability genetic 
algorithm
N/A N/A clinical Marvin et al, 
blastic 1999
any newly published machine learning model 
should be compared against either another kind of 
learning model, a traditional statistical model or 
an expert-based prognostic scheme such as the 
TNM staging system. As seen in Table 2, some-
times the more sophisticated machine learning 
methods do not lead to the best predictors. In some 
cases, traditional statistics actually outperform 
machine learning methods (Kaiserman et al. 2005; 
Kim et al. 2003). Unfortunately, only about 17% 
of the papers reviewed here tested more than one 
machine learning classiﬁ  er.74
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It is also important to remember that the 
machine learning process is essentially a compu-
tational experiment. Like any experiment it is 
based on a hypothesis, it follows deﬁ  ned proce-
dures and it requires data to be validated. Because 
machine learners represent true experimental pro-
cedures, they should be treated as such. Therefore 
detailed methodological documentation is of para-
mount importance. Ideally, the data sets used for 
training and testing should be described in detail 
and made available to the public. Information 
about training and testing data should also be well-
described including the way in which the sets were 
partitioned. Likewise the details regarding the 
algorithms used and their implementations 
should be provided or recorded to permit others to 
verify and reproduce the results. In principle, the 
results from a good machine learning experiment 
should be as reproducible as any other standard lab 
protocol.
Conclusion
In this review we have attempted to explain, com-
pare and assess the performance of different 
machine learning that are being applied to cancer 
prediction and prognosis. Speciﬁ  cally we identiﬁ  ed 
a number of trends with respect to the types of 
machine learning methods being used, the types 
of training data being integrated, the kinds of end-
point predictions being made, the types of cancers 
being studied and the overall performance of these 
methods in predicting cancer susceptibility or 
outcomes. While ANNs still predominate it is 
evident that a growing variety of alternate machine 
learning strategies are being used and that they are 
being applied to many types of cancers to predict 
at least three different kinds of outcomes. It is also 
clear that machine learning methods generally 
improve the performance or predictive accuracy 
of most prognoses, especially when compared to 
conventional statistical or expert-based systems. 
While most studies are generally well constructed 
and reasonably well validated, certainly greater 
attention to experimental design and implementa-
tion appears to be warranted, especially with 
respect to the quantity and quality of biological 
data. Improvements in experimental design along 
with improved biological validation would no 
doubt enhance the overall quality, generality and 
reproducibility of many machine-based classiﬁ  ers. 
Overall, we believe that if the quality of studies 
continues to improve, it is likely that the use of 
machine learning classiﬁ  er will become much 
more commonplace in many clinical and hospital 
settings.
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